Key Highlights:
- Lucid Diagnostics shares rose 24.41% to $0.4077 on Friday, October 23, 2026, after an October 22 announcement.
- Medicare payments for the EsoGuard test began at $1,938.01 per test.
- A $15.0 million Series C convertible preferred placement closed on October 21 at a $0.3519 conversion price.
- Second-quarter revenue rose to $1.474 million from $1.163 million a year earlier.
- Cash and equivalents were $33.4 million on June 30, 2026, against a quarterly net loss of $11.687 million.
Lucid Diagnostics Stock: Why Is the Penny Stock Up 24% Despite a $15 Million Preferred Raise?
Lucid Diagnostics (NASDAQ:LUCD) shares rose 24.41% to $0.4077 on Friday, October 23, 2026, from a prior close of $0.3277 (calculated). The move followed a company announcement on October 22, issued after the close, that Medicare has started paying for its EsoGuard test and that a $15.0 million private placement has closed.
Investors appeared to weigh the reimbursement milestone more heavily than the dilution. The Series C convertible preferred stock was sold to existing long-term shareholders at $1,000 per share and converts into common stock at $0.3519 per share.
Lucid develops EsoGuard, an esophageal DNA test used to detect precancerous changes linked to Barrett's esophagus, and EsoCheck, a device that collects cells from the esophagus without an endoscopy.
Medicare Payments: How Much Does EsoGuard Now Earn per Test?
The company said it began receiving Medicare payments for claims from one of its two laboratories, at a rate of $1,938.01 per test.
Second-quarter revenue was $1.474 million across 2,770 EsoGuard tests processed, or roughly $532 per test (calculated). The Medicare rate is about 3.6 times that average (calculated), though not every test will be billed to Medicare.
A September 22 update had outlined the path. A federal advisory panel on laboratory test pricing backed keeping EsoGuard's original payment basis under code 0114U, with final determinations expected in November after public comment. The American Medical Association panel also approved a new Category III code for cell collection with EsoCheck, which is not yet effective.
Financing Terms: What Does the Series C Preferred Mean for Shareholders?
The $15.0 million raise closed on October 21 and will fund near-term commercial operations, working capital and general corporate purposes. At $1,000 per preferred share, the placement equals about 15,000 shares (calculated), each convertible into roughly 2,841 common shares (calculated).
If fully converted, the placement would add about 42.6 million common shares (calculated). Basic and diluted weighted shares were 183.1 million in the second quarter, so the placement represents roughly 23% of that count (calculated).
Financial Context: How Large Are the Losses Against the Cash Position?
For the quarter ended June 30, 2026, Lucid reported a net loss of $11.687 million. Operating expenses were $14.275 million, including $1.7 million of stock-based compensation, and the adjusted non-GAAP loss was $10.854 million, or $0.06 per share.
Cash and equivalents were $33.4 million on June 30, down from $34.7 million at the end of 2025. Six-month revenue reached $2.730 million, up from $1.991 million a year earlier.
At $0.4077 and the 183.1 million second-quarter weighted shares, the equity value is about $75 million (calculated). The company gave no financial guidance in that release.
What to Watch Next: Can Medicare Payments Turn Test Volume Into Revenue?
The takeaway is that reimbursement has moved from expectation to cash receipts at one laboratory, while a convertible placement adds potential share count. The next dated catalyst is the final Medicare payment determination expected in November 2026; third-quarter results have not been scheduled, and second-quarter results were reported on August 13.
The company announced that Medicare began paying $1,938.01 per EsoGuard test and that a $15.0 million Series C preferred placement had closed.
Each preferred share, sold at $1,000, converts into common stock at $0.3519 per share.
Cash and equivalents were $33.4 million on June 30, 2026, before the $15.0 million placement.






Please wait processing your request...